Goldman Sachs Initiates Buy Recommendation on BrightSpring Health with $71 Target

SentiSense · Published · Updated

Goldman Sachs has initiated coverage of BrightSpring Health with a 'Buy' recommendation and a target price of $71. This news may impact investors' con...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis